Information about http://www.merck.de/company.merck.de/en/images/09_Vorstand_22_11_05_eng_tcm82_17799.pdf

…

Tags: 24 years, bernhard scheuble, business sector, dr frank, dr michael, environmental issues, general partners, great reputation, impressive growth, information fax, investor relations, merck, merck family, merck kgaa, michael roemer, new jobs, ohg, pharmaceutical business, production engineering, vice chairman,
Pages: 2
Language: english
Created: Tue Nov 22 18:38:00 2005
Display cached document
Page 1
image
Page 2
image
                                                                     Your Contact
                                                                     investor.relations@merck.de
Investor Relations Information                                       Fax: +49 6151 72-913321



November 22, 2005


Merck KGaA Announces New Leadership


    ·      Dr. Michael Roemer is named chairman of the executive board with immediate
           effect.
    ·      Former chairman of the executive board Prof. Dr. Bernhard Scheuble leaves the
           company.
    ·      Elmar Schnee joins the executive board and will be responsible for the
           Pharmaceutical Business Sector.


The Chairman of the Executive Board of E. Merck OHG, Jon Baumhauer, announced that the
board unanimously decided to name Dr. Michael Roemer, 59, as chairman of the executive
board of Merck KGaA with immediate effect. Dr. Roemer will maintain his current
responsibility for production, engineering, corporate purchasing, environmental issues and
logistics sectors.


Vice Chairman of the Executive Board of E. Merck OHG, Dr. Frank Stangenberg-Haverkamp,
stated: "With Michael Roemer we have appointed a chairman, who in his 27 years with the
company, has built a great reputation widely recognized internally and externally. We are
pleased that he will lead the company into the next management generation."


Prof. Dr. Bernhard Scheuble, 52, is resigning with mutual agreement with immediate effect.
Jon Baumhauer, spokesman for the Merck family, said, "In the 24 years that Professor
Scheuble worked for our company, he achieved an impressive growth in our corporate value
and created new jobs. We are thankful for his great contribution and wish him well for the
future."


                                                                                                      Page 1 of 2
Merck KGaA · Germany
Investor Relations       Partnership limited by shares                 Executive Board and General Partners:
Frankfurter Straße 250   Commercial Register AG Darmstadt HRB 6164     Bernhard Scheuble (Chairman),
64271 Darmstadt          Registered Office Darmstadt                   Michael Römer (Vice Chairman),
www.investors.merck.de   Chairman of the Supervisory Board:            Michael Becker, Thomas Schreckenbach,
                         Peter Zühlsdorff                              Jan Sombroek, Walter W. Zywottek
Investor Relations Information



Also with immediate effect, Elmar Schnee, 46, will become a member of the executive board
of Merck KGaA and will be responsible for the Pharmaceutical Business Sector, which until
now was also led by Professor Scheuble. Schnee has broad experience in the
pharmaceutical business and accomplished extraordinary achievements in various markets
especially in France. He will keep his responsibility for the Pharma Ethicals division for the
time being.




Your Investor Relations Team:
Dr. Christian Raabe Tel.: +49 6151 72-6295
Sascha Becker        Tel.: +49 6151 72-3321
Dr. Monika Buttkereit Tel.: +49 6151 72-2584
Susanne Zeichner     Tel.: +49 6151 72-3315




                                                                                      Page 2 of 2